title: IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease.
abstract: The Fifth International Pharmaco-Economic Conference on Alzheimer's Disease was held in New York, on March 27-29 in 2008. The attendees included researchers and key opinion leaders within the academia, pharmaceutical industry, patient organizations and regulatory bodies, collecting the worldwide leading expertise in Alzheimer research today. A summary of the presentations and conclusions from the discussions are presented in this publication. Pharmaco-economics need to play a leading role in developing and communicating evidence of the value of anti-dementia drugs, now and in the future. For the development of evidence, the challenges include transparency and standardization of costs of care assessment, improved diagnostics for identifying target patient groups, improved endpoints for assessing outcomes and improved models for assessing the long term consequences of competing treatment strategies. For the communication of evidence, the challenge lies in convincing decision makers to recognize the integrated burden of the disease, including its interaction with co-morbidities and burden on caregivers, and to consider the consequences of competing treatment strategies from a societal perspective.
authors.affiliation: KI Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska institutet, Novum plan 5, 141 86 Stockholm, Sweden. anders.gustavsson@ki.se
authors.forename: A
authors.initials: A
authors.lastname: Gustavsson
authors.forename: L
authors.initials: L
authors.lastname: Jonsson
authors.forename: H
authors.initials: H
authors.lastname: Fillit
authors.forename: G
authors.initials: G
authors.lastname: Johansson
authors.forename: A
authors.initials: A
authors.lastname: Wimo
authors.forename: B
authors.initials: B
authors.lastname: Winblad
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D017048:Health Care Costs; D006801:Humans; D008875:Middle Aged; D018803:Models, Economic; D018696:Neuroprotective Agents / Q000191:economics* / Q000627:therapeutic use; D018697:Nootropic Agents / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D018697:Nootropic Agents